Please assess the completion status of the following clinical trial:

Trial Title: Pharmacologically-based Strategies for Opioid Substitution Therapy During Pregnancy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. On a stable dosing regimen of BUP for at least 2 weeks as part of an established medication- assisted treatment (MAT) program.~2. Willingness to undergo supervised dose reduction~3. Subject willingness to be assigned to either the Magnitude, or Frequency group.~4. Single gestation between 14-30 weeks at the initiation of the dose reduction~5. On a BUP dose between 6- 24 mg daily (lower doses will not provide sufficient data points)~6. Willingness to have urine samples tested for drugs of abuse and blood samples tested for BUP+M concentrations during the Medical Supervised Withdrawal (MSW) clinic appointments~7. Willingness to attend weekly or biweekly MSW clinic appointments and to have daily contact via text messaging and to complete daily logs of sleep quality, withdrawal symptoms and symptoms of craving.~8. Willingness to attend psychosocial support meetings as needed.~Exclusion Criteria:~1. Current use of cocaine, heroin, benzodiazepines, barbiturates, phencyclidine (PCP), or opioids other than BUP.~2. Currently taking more than two mental health medications~3. Active moderately severe depression (PHQ-9 score ≥15 or suicidal ideation)~4. Current incarceration~5. Lack of a phone or transportation to and from clinic~6. Major fetal malformation~7. Mother with significant vaginal bleeding or serious medical or obstetrical complication that could adversely affect the study~8. Planned delivery at another institution~9. HIV or AIDS~10. Diagnosis of schizoaffective disorder or psychosis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Magnitude Group (Type: ACTIVE_COMPARATOR): Subjects will receive alternating reductions of 1 mg or 2 mg weekly.
- Frequency Group (Type: ACTIVE_COMPARATOR): Subjects will receive dose reductions of 2 mg on alternating intervals of 1 and 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).